ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An Express License provides fast, simple and affordable access to the CRISPR/Cas9 patent portfolio through a non-exclusive internal research license. DUBLIN and CHESHIRE, United Kingdom, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ERS Genomics (‘ERS’), the CRISPR licensing company, today announces the launch of its Express License platform to provide small research enterprises and startups with affor ...